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REPRODUCIBILITY CRISIS IN SCIENCE:  
CAUSES AND POSSIBLE SOLUTIONS 
 
DANIEL A. DRIMER-BATCA 
 
ABSTRACT 
Part I. Claims to knowledge require justification. In science, such justification is 
made possible by the ability to reproduce or replicate experiments, thereby 
confirming their validity. Additionally, reproducibility serves as a self-correcting 
tool in science as it weeds out faulty experiments. It is therefore essential that 
experimental studies be replicated and confirmed. Recently, attempts to 
reproduce studies in several fields have failed, leading to what has been referred 
to as "a crisis of reproducibility." This crisis is largely a result of the current 
culture in the scientific world. Specifically, it is a result of a system that 
incentivizes individual success in the form of publications in high-impact journals 
over collaboration and careful conductance of research. This environment 
contributes to the crisis of reproducibility by increasing biases, incentivizing 
researchers to engage in manipulative statistics, decreasing quality control and 
transparency, and increasing the likelihood of researchers engaging in fraudulent 
behavior. 
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Possible solutions to the problem of irreproducibility could tackle individual 
factors. A more prudent approach would be to focus on changing the current 
culture in the scientific world. Increased transparency had been suggested as a 
way to solve this problem. There is currently a movement advocating for 
increased transparency in science through "open science." 
 
Part II. Retraction of scientific papers due to evidence of research misconduct is 
on the rise, having increased tenfold from 2000 to 2009. Previous work on this 
topic focused on published retraction notices, using notices to identify the percent 
of retracted articles that were caused by research misconduct. This study utilized 
a different approach. Using the Office of Research Integrity database, we first 
identified publications that resulted from research misconduct. We then searched 
those articles to determine whether they were indeed retracted. Once retraction 
notices were identified, they were scored based on scoring elements reflecting 
guidelines for transparency. Lastly, we investigated whether a correlation exists 
between the quality of a retraction notice and journal impact factor. Our findings 
suggest that 21% of papers containing data derived from scientific misconduct 
are not retracted. Moreover, the quality of retraction notices varies, with some 
elements more likely to be present than others. No significant correlation 
between retraction notices and journal impact factor was found.    
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PART I 
INTRODUCTION 
 
The first part of the thesis will explore the so-called crisis of reproducibility, 
including the background to the problem, its extent, and significance. In 
particular, the reasons for the crisis will be investigated, and the remediation 
strategies that have been proposed or implemented will be described.  
 
Importance and Historical Background of Reproducibility in Science  
Science, as an enterprise, is concerned with obtaining knowledge about the 
universe through the implementation of the scientific method. While the question 
of what constitutes knowledge—or if we can ever truly know anything—is a 
contested topic, I believe most would agree with Plato’s definition of knowledge 
as a “justified true belief.” To claim something to be known requires, at the very 
least, some degree of justification for that claim. And since science is concerned 
with obtaining knowledge, it must provide justification for the validity of its 
findings. Reproducibility, or replicability, allows scientists to weed out false claims 
or bad science, thereby ensuring that the results of a scientific experiment are 
correct. In fact, successfully reproducing an experiment is one of the few tools 
available to scientists in their pursuit of justification—so much so that philosopher 
Karl Popper once stated: “Non-reproducible single occurrences are of no 
significance to science” (Popper, 1959). It is important to note that reproducibility 
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does not necessarily provide us with knowledge that the conclusion of an 
experiment is true. For example, the observation that maggots will eventually 
appear in unrefrigerated raw meat does not provide justification for the theory of 
spontaneous generation. Similarly, reproducibility is not an essential requirement 
for all scientific fields (after all, we cannot replicate the evolution of human life, or 
the big bang, in a laboratory). So while reproducibility does not guarantee the 
validity of conclusions derived from experimental results, it confirms the validity of 
the process that leads to them and is, therefore, a cornerstone of experimental 
science and the scientific method. 
 
The importance of reproducibility in science had been known for centuries. In 
their 1985 book, Leviathan and the Air-Pump, Shapin and Schaffer describe a 
well-documented debate between the 17th-century scientists Robert Boyle and 
Thomas Hobbes. The debate revolved around the integrity of Boyle’s newly 
invented air-pump, a machined he used to study the properties of air and, 
specifically, the controversial concept of a vacuum. After learning that the Dutch 
scientist Christiaan Huygens was able to levitate a drop of water inside a jar 
using his own version of the air-pump, Boyle attempted to replicate the 
experiment with no success. Convinced that unless the experiment could be 
replicated, the value of its findings would be questionable, Boyle invited Huygens 
to England and together they were able to reproduce the phenomenon. While 
Hobbes denied the existence of a vacuum, Boyle maintained that by successfully 
 3 
repeating the experiment, its findings could not be denied. At its core, the debate 
was about the proper way of obtaining knowledge—with Boyle’s notion that it 
should be through the conduction of experiments and their successful 
reproduction prevailing. 
 
More recently, however, concerns have been raised regarding the reproducibility 
of many published experiments. Irreproducibility had been reported to varying 
degrees in fields such as medicine, chemistry, engineering, environmental 
science, and psychology, to name a few (Baker, 2016). As attention given to the 
problem increases so does our understanding of its extent, and today many 
scientists talk of a “crisis of reproducibility.” 
 
The Reproducibility Crisis  
In 2016, the journal Nature published the results of a survey completed by 1,576 
scientists from various fields (Baker, 2016). Over 70% of polled researchers 
admitted to having attempted and failed to reproduce another researcher’s 
published experiments, and more than half reported failing to reproduce their 
own experiments. When asked whether there is a reproducibility crisis, 90% of 
surveyed researchers stated that there is either a significant or slight crisis. Only 
3% held the view that there is no crisis.  
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The poll showed that the problem of irreproducibility affects many fields, including 
biology, physics and engineering, environmental science, and medicine (Baker, 
2016). Data suggest that the most affected fields are psychology and 
biomedicine. In 2012, researchers attempted to reproduce the results of 53 
cancer studies, which they had deemed “landmark” studies. They failed to 
reproduce 47 of the 53 papers (Begley & Ellis, 2012). Other studies have also 
tried and failed to replicate the results of many preclinical biomedical studies 
presented in prestigious journals with irreproducibility numbers ranging from 75% 
to 90% (Yaffe, 2015). A similar problem of irreproducibility exists in observational 
studies, with Ioannidis reporting that 80% of such studies either fail to be 
replicated or yield results that are significantly smaller than originally stated 
(Ioannidis, 2015). Similarly, in one of the largest replication study in psychology, 
conducted in 2015 by Brian Nosek et al., attempts to replicate 100 original 
studies published in three psychology journals were successful in only 39 of the 
100 papers (Baker, 2015). A separate study from that same year, which 
attempted to replicate a separate set of 100 psychology papers, achieved 
statistical significance in 36% of replications, compared with 97% in the original 
studies (Aarts et al, 2015). 
 
Failure to replicate experiments is especially impactful when it occurs in the basic 
sciences or in preclinical studies, as those types of studies provide the 
background and basis for future experiments. Preclinical studies, in particular, 
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serve as the basis for new drug development, an expensive and resource 
consuming process. Irreproducibility of preclinical studies, which suggests 
potential problems with the original experiments, has the potential to affect the 
success of drug development. Indeed, recent studies have blamed the declining 
success rates of Phase II trials for new drug developments on the irreproducibility 
of much of the published data which serves as the basis for the drug 
development (Prinz, Schlange, & Asadullah, 2011). 
 
Defining the Terms—What Constitutes Reproducibility? 
As the attention given to—and publications on the topic of—the problem of 
irreproducibility increases, questions have been raised regarding the terms used 
to describe the problem, and their meaning (Oransky & Marcus, 2016).  
 
According to a 2015 report by the National Science Foundation Subcommittee on 
Replicability, reproducibility means “the ability of a researcher to duplicate the 
results of a prior study using the same materials and procedures as were used 
by the original investigator. [For example], a researcher uses the same raw data, 
builds same analysis files, and same statistical procedures to make sure that 
same results obtained as in published study.” Replicability, on the other hand, 
refers to “the ability of a researcher to duplicate the results of a prior study if the 
same procedures are followed but new data are collected.” (Bollen, 2015). The 
same report also acknowledges the lack of a consensus in science on the 
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meaning of these terms, noting that different terms can refer to the same thing, 
while the same term can be used to describe different things. Given the lack of 
an agreed upon definition, it is often hard to know what researchers mean when 
using these terms. 
 
Furthermore, it is not clear from the definitions of these words what constitutes 
reproducibility or replicability. For example, it is not clear whether successful 
reproduction entails complete agreement between the results of the original and 
replication study, or if small deviations that do not alter the conclusion fall under 
successful reproduction. It is similarly unclear whether studies that yield the 
same data but are interpreted differently constitute successful reproduction. 
 
A recent paper by Goodman, Fanelli and Ioannidis (2016) suggests that many of 
the terms used in discussing this issues are proxies for the word “truth,” a fact 
they criticize. They conclude their paper by pointing out the importance of 
defining these terms in a universally accepted manner, and of better 
understanding the relationship between the terms we use and the truth of a 
scientific claim.  
 
 
 
 7 
Specific Aims 
Specific aims of the first part of this thesis include the following: 
1. Review of relevant literature to identify reasons for the crisis in 
reproducibility.  
2. Analysis of possible solutions to the crisis in reproducibility. 
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WHY DO SCIENTISTS FAIL TO REPRODUCE RESEARCH? 
 
Numerous reasons have been identified as contributing factors to the crisis of 
reproducibility. While varying, a common factor for those reasons is the 
“overflow” of science. Siebert et al. offer the following explanation. An increased 
demand for limited resources in the scientific world, such as jobs, postdoctoral 
positions, and grants, combined with a perceived decrease in funding, had led to 
increased pressure to produce results. Given this so-called overflow, publications 
in high-impact journals have become a measuring stick for success. This, in turn, 
creates increased pressure on scientists to produce high-impact publications, to 
the point where the publications themselves, and not the science behind them, 
had become the goal of scientists (Siebert, Machesky, & Insall, 2015). As will be 
discussed shortly, the increased pressure to publish and the sheer amount of 
science being produced has led to biases, decreased quality control and 
transparency, and other factors that have contributed to the problem of 
reproducibility. 
 
Biases 
Biases have been known to affect thought and reasoning for centuries. Francis 
Bacon identified four types of biases, which he called idols, as early as 1620, in 
his philosophical work Novum Organum. Today, biases continue to affect human 
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reasoning and the way we conduct science. These biases come in different 
forms and are exacerbated by increased competition and pressure to publish.  
 
Perhaps the most obvious type of bias, referred to by Bacon as “idols of the 
cave,” is personal biases. Such biases are often unconscious, and stem from the 
desire to support one’s theory, to refute an opposing theory, or to publish a new 
discovery on a topic. These biases affect how investigators conduct experiments 
or analyze data, and could even lead researchers to overlook calculation 
mistakes if the results are aligned with their expectations (Nuzzo, 2015; Maccoun 
& Perlmutter, 2015).  
 
Another, perhaps less obvious, type of bias is publication bias—a term referring 
to the fact that research findings are either published or not publication 
depending on the nature of the results (Dickersin, 2005). The idea behind 
publication bias is that in an ideal scientific world, the valid results of every 
legitimate, well conducted and honest study should be published. In such a 
world, the scientific literature would reflect the true and full body of research that 
had been conducted on a specific topic, with no artificial biases towards certain 
outcomes. Yet this is not the case. In today’s scientific landscape, the results of a 
significant proportion of conducted studies are never made public. This fact had 
been known since at least 1959, when a paper by Sterling noted that an 
astonishing 97% of studies published in a number of reputable psychology 
 10 
journals reported statistically significant results (Sterling, 1959). In that same 
paper, Sterling coined the term “publication bias” to refer to the fact that 
“successful” studies—that is, studies with positive and statistically significant 
results—are more likely to be published. In 1979, Rosenthal further commented 
on this issue, terming it “the file-drawer problem,” in reference to the fact that 
results which do not support the researchers’ hypothesis end up in the file 
drawer, rather than in a journal (Rosenthal & Hernstein, 1979). More recently, it 
was suggested that as many as 95.8% of papers on the topic of cancer 
prognostic markers reported statistical significance (i.e. positive results) (Kyzas, 
Denaxa-Kyza, & Ioannidis, 2007). Additional studies have taken different 
approaches to investigating this phenomenon. A 2013 study utilized a database 
containing all drug-evaluating clinical trials approved by the Ethics Committee of 
a Spanish hospital over a period of 7 years. The study found that the publication 
rate in peer-reviewed journals for completed trials with positive results was 
84.9%, compared with 68.8% for studies with negative results. The researchers 
concluded that trials with positive results were more likely to get published than 
those with negative results (Sune, Sune, & Montoro, 2013). There is also direct 
evidence for this phenomenon in the form of admission to bias by parties 
involved in the publication process (Song et al, 2009). 
 
A closely related problem to the non-publication of negative results is that of 
outcome reporting bias. Outcome reporting bias, which affects published papers, 
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is defined as the selective reporting of some, but not all, outcomes. A 2013 study 
by Riveros et al. investigated selection bias by utilizing the fact that the US Food 
and Drug Administration (FDA) Amendments Act requires results from clinical 
trials of FDA-approved drugs to be made available in an online database. The 
researchers compared the results of clinical trials as they appeared in the online 
database with the results of the same studies as they were presented in 
published journals. They found that the results in the online database were far 
more complete and included findings that were not presented in journal 
publications, suggesting the existence of a selective reporting bias (Riveros et al, 
2013). Other studies have confirmed that statistically significant results are more 
likely to be fully reported, whereas non-significant results are more likely to be 
partially reported (Dwan et al, 2008).   
 
Interestingly, the relative lack of negative results in the literature is not so much a 
result of journals failing to publish such papers, but of researchers failing to 
submit them. An analysis of 745 manuscripts submitted for publication in JAMA 
revealed only a slight, statistically-insignificant increased rate of publication for 
studies with positive-results over those with negative-results (Olson et al, 2002). 
A study looking into publication bias in clinical trial reporting similarly concluded 
that non-publication was mostly a result of failure to submit manuscripts, not of 
rejection by journals (Dickersin et al, 1987). Such findings would be expected 
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given the overflow in science and the increased pressure on scientists to make 
new, impactful discoveries.  
 
Fanelli, Costas, and Ioannidis (2017) identify additional bias patterns which 
negatively impact the scientific literature. The “small-study effect” refers to the 
observed phenomenon of smaller studies showing larger, more significant 
treatment effects than large studies (Schwarzer, Carpenter, & Rücker 2015). A 
particular problem that arises from the presence of small-study effects is their 
impact on meta-analysis reviews. Meta-analysis reviews are believed to provide 
better evidence than any single study on a specific topic, which they achieve by 
pooling the results of many studies on a particular subject. However, meta-
analyses that include many small studies have the potential of being slanted 
towards a particular result, which is not reflective of the truth. It had been 
suggested that the small-study effect is likely due to a combination of factors. 
Some of those factors, like publication or reporting biases, have been discussed 
previously. Other factors include low methodological quality of small studies, 
such as a bias towards selecting participants who are more likely to produce 
significant results, or mere-coincidence (Nuesch et al, 2010; Schwarzer et al, 
2015).  
 
Another observed phenomenon is the diminishing effects obtained when 
repeating a study. Stated differently, earlier studies reporting a certain effect are 
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likely to overestimate the effect’s magnitude relative to later studies. This has 
been termed “the decline effect,” and is attributed to the decrease in publication 
bias on a specific topic over time (Schooler, 2011). A related phenomenon is the 
“early-extreme effect,” which describes the increased likelihood of early studies 
to report extreme effects. This too is attributed to the publication bias, as extreme 
findings are more likely to be published early (Ioannidis & Trikalinos, 2005).  
 
Citation bias describes the fact that studies with strong magnitudes of effects and 
large statistical significance are more likely to be cited. Since it is common to look 
for references in articles when investigating a certain question in the literature, 
citation bias may lead to a distorted view of the field (Jannot et al, 2013).  
 
Lastly, industry bias is associated with the increased role of industries in the 
scientific world, and the financial support they provide for research. The 
increased involvement of companies in scientific research has been linked to 
increased reporting bias in the literature. A 2003 study found that research 
funded by drug companies is less likely to be published than research funded 
from other sources, and that the results of published industry-funded research 
are more likely to have results favorable to the sponsor (Lexchin et al, 2003).  
 
These bias patterns diminish reproducibility in multiple ways. Personal biases do 
so by potentially introducing sloppy work or questionable practices to studies. 
 14 
Attempts to reproduce such studies by scientists who do not share the same 
motivations as the original researchers might, therefore, alter how the research is 
conducted or what data is used, and could result in unsuccessful attempts to 
replicate original studies. Publication and outcome reporting biases affect 
irreproducibility by creating a scientific literature in which certain results are 
overrepresented. Since the overrepresentation of those results is not an accurate 
representation of all sampling done by researchers, it is not a true representation 
of those phenomena in the world. It thus follows that attempts to reproduce those 
studies in an unbiased matter are more likely to fail than succeed. Lastly, biases 
such as small-study and decline effects lead to results that can often be 
explained by small sample sizes and poor statistics. Attempts to reproduce such 
studies with larger sample sizes are likely to obtain different conclusions, thus 
making the original studies irreproducible. 
 
Bad Statistics  
An issue closely related to the biases discussed above, bad statistics are another 
reason some findings cannot be reproduced. The pressure to publish once again 
plays a role, as it incentivizes researchers to engage in practices that increase 
the likelihood of finding significant results. Some of those practices include using 
flexible statistical analyses and conducting small studies with low statistical 
power. Of particular consequence is the issue of low statistical power. It has 
been shown that low statistical power (due to small sample size) affects studies 
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in three ways. First, it reduces the likelihood of detecting a true effect. Second, it 
reduces the likelihood of statistically-significant results being a true 
representation of an effect. Third, even when describing a true effect, it tends to 
exaggerate its magnitude (Button et al, 2013). Given these facts, it is 
disconcerting that many studies have been found to have low statistical power. A 
study published in Nature concluded that the average statistical power of studies 
published in the field of neuroscience is between 8% and 31% (Button et al, 
2013). For comparison, the conventionally accepted minimum value for statistical 
power is 80%. Similarly, a 2017 study of statistical power in biomedical science 
found that approximately half the studies had statistical power in the 0% to 20% 
range (Dumas-Mallet et al, 2017). To illustrate what this means for 
reproducibility, consider a study with a 20% statistical power. By definition, 
conducting an exact replication of such a study will, on average, only yield the 
same results 20% of the time.   
 
An additional practice that had been suggested as contributing to the probability 
of obtaining false-positive results is flexibility in data collection. Data-collection 
flexibility refers to the practice of either continuing data collection until the desired 
result is obtained, or ceasing data collection as soon as one is found (Nosek, 
Spies, & Motyl, 2012). In a 2011 survey, approximately 70% of polled behavioral 
scientists admitted to having engaged in data-collection flexibility at least once 
(John, Loewenstein, & Prelec, 2012). Additionally, Simmons et al. conducted 
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statistical analyses that show how a continuous increase in sample size leads to 
fluctuations in p-values, further illustrating how data-collection flexibility can 
impact results (Simmons, Nelson, & Simonsohn, 2011) 
 
Quality Control 
Another consequence of the pressure to publish is a willingness to forgo 
adequate quality control measures when conducting experiments, for the sake of 
expediency. One major quality control issue, which affected scientists for over 50 
years, is the cross-contamination, misidentifying and mislabeling of cell lines 
(Freedman et al, 2015). Immortal cell lines are cells which, due to mutations that 
cause loss of cell cycle checkpoint pathways, are able to proliferate indefinitely in 
vitro (Irfan Maqsood et al, 2013). Such cells are widely used in laboratories as a 
model to study multicellular organisms, and to develop new drugs. Consequently, 
when a laboratory purchases a specific cell-line, which they believe to be derived 
from a specific type of cancer, they might, in fact, be unknowingly working with 
cells derived from a different type of cancer. They may even be working with cells 
derived from a different species (McCook, 2015). The fact that cross-
contamination and misidentification of immortal cell-lines is a problem has been 
known since at least 1966, yet as of 2012, an estimated 15% of human cell lines 
were not derived from the claimed source (Masters, 2012). Despite the 
prevalence of this problem, efforts to curb the phenomena had only recently 
gained traction (Nardone, 2008). To that end, in 2012 the International Cell Line 
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Authentication Committee (ICLAC) was established in order to “make cell line 
misidentification more visible and to promote awareness and authentication 
testing as effective ways to combat it” (http://iclac.org/about-iclac/). As of 
February 2018, the ICLAC database lists 451 cell lines that are misidentified, and 
49 cell lines that come from different species.  
 
This issue can have costly consequences. Take for example the case of 
Radoslaw Stachowiak, who, in October 2014, published a paper in Current 
Microbiology comparing how Listeria invades three different cell lines. When the 
authors found out that all three cell lines investigated were in fact derived from a 
single source—the HeLa cell-line—they were forced to publish a correction to 
their paper (Stachowiak et al, 2015). Such a mistake is not only costly due to the 
time and money spent by the original team who published the findings, but also 
due to the amount of citations these studies receive, and the lost time and effort 
to reproduce these sometimes unreproducible findings (Neimark, 2015).  
 
These problems are accentuated by a number of factors. An article by Freeman 
et al. identifies a number of problems which contribute to the irreproducibility of 
papers due to cell-line misuse (Freedman et al, 2015).  For one, there are data to 
suggest that most laboratories fail to conduct cell line authentication before 
publishing a paper; a 2014 Nature Cell Biology editorial reporting the results of 
an audit of papers published between August to December 2013 showed that 
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only 19% of publications authenticated cell-lines used in their studies (An update 
on data reporting standards, 2014). Sharing of cell-lines among scientists, as 
opposed to obtaining such cells from a reputable source such as a cell bank, is 
another contributing factor. In addition, Freeman et al. identified the lack of 
cheap, fast, and commercially available authentication techniques, as a problem. 
The article also notes the lack of universally enforced reporting guidelines for 
reporting cell authentication in publications. Having such guidelines in place, they 
claim, would “help ensure the credibility, reproducibility and translatability of the 
data and results” (Freedman et al, 2015). 
 
The issue of quality control is not limited to cell-line contamination. As part of an 
effort to create a drug screening library, Corsello et al. sought to confirm the 
identity and purity of 8,584 chemical compounds sourced from different vendors. 
To their surprise, they found that 2,482 compounds, comprising 29% of the 8,584 
testes, failed quality control standards (defined as impurities making up 15% or 
more of the reagent) (Corsello et al, 2017). Such impurities directly impact the 
ability of researchers to conduct and replicate experiments. Take for example the 
case of a Stefan Knapp, a German scientist who obtained three different results 
when conducting the same experiment on three different occasions, each time 
using the same compound sourced from a different vendor (Bakes, 2017). A 
similar incident occurred in 2012, when 18 separate vendors were found to be 
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supplying the wrong compound, which they advertised as the leukemia drug 
bosutinib (Levinson, Boxer, & Ramchandran, 2012). 
 
Data Interpretation 
Shortly after Rafael Silberzahn and Eric Uhlmann published their findings that 
Germans with noble-sounding surnames, such as Kaiser (“emperor”) or König 
(“king”) are more likely to hold managerial positions than Germans with 
surnames that refer to everyday occupations such as Bauer (“farmer”) or Becker 
(“baker”), they received a request for their dataset (Silberzahn & Uhlmann, 2013; 
Silberzahn & Uhlmann, 2015). Using the same dataset that yielded the original 
conclusion, Uri Simonsohn showed that there is, in fact, no correlation between 
noble-sounding last names and holding managerial positions. Together, the three 
authors published a paper refuting the original conclusion (Silberzahn, 
Simonsohn, & Uhlmann, 2014).  
 
This experience led Silberzahn and Uhlmann, along with Dan Martic and Brian 
Nosek, to investigate how different teams may interpret similar datasets. To do 
so, they conducted an experiment in which 29 teams of analysts received the 
same dataset, which included a number of variables pertaining to soccer players 
and referees. The teams were asked whether the data support the claim that 
dark-skinned soccer players are more likely to receive red cards. An analysis of 
the results showed that different teams took different approaches to analyzing 
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the data, using different variables from the dataset, with 20 teams finding a 
statistically significant correlation between skin tone and the likelihood of 
receiving a red card, while 9 teams found no significant correlation (Silberzahn et 
al, 2017). 
 
The results of this experiment show the power of subjectivity, in the form of which 
variables researchers choose to use and what statistical analysis they conduct, 
on the way data is interpreted and therefore on the final outcome of a study. Had 
any one of the teams’ results been published, it would have been cited and 
become part of the scientific literature. Yet with multiple different conclusions 
from the same dataset—one is left wondering which conclusion is the “right” one. 
Moreover, this study illustrates how data interpretation adds an additional layer to 
the problem of reproducibility.  
 
Data Sharing and Protocol Availability 
In a 1675 letter to Robert Hooke, Isaac Newton famously declared “If I have seen 
further it is by standing on the shoulders of Giants." As a field where progress is 
made by building on previous knowledge, science depends on the sharing of 
information. The practice of transparency in science cannot be limited to the 
sharing of results, but must also include the necessary tools to allow 
authentication and replication of results. It is therefore paramount that scientists 
publish the datasets used to obtain their results, along with protocols describing 
 21 
how their research was conducted. Doing so benefits the scientific community in 
multiple ways. It allows for datasets to be fully explored and analyzed, while also 
increasing the likelihood of detecting errors in the original study, thereby reducing 
the likelihood of scientific fraud, and making science more efficient and overall, 
more trustworthy (Duke & Porter, 2013; Vanpaemel et al, 2015). 
 
Yet despite the obvious importance of sharing data and protocols, it is not 
ubiquitously practiced. Take for example the field of psychology, where 
reproducibility is notoriously difficult (Pashler & Wagenmakers, 2012). Despite a 
2015 report in which a team of psychologists failed to reproduce 61 of 100 
psychology studies (Baker, 2015 April), researchers remain reluctant to share 
their data. When Vanpaemel et al. (2015) contacted the authors of 394 papers 
published in APA journals during 2012 with a request to share their data, only 
38% of researchers did so. Other fields suffer from similar reluctance as well. In 
2002, 47% of geneticists who had tried to receive additional data on published 
articles, reported having been denied access at least once in the preceding 3 
years (Campbell et al, 2002). More recently, a study looking at the availability of 
raw data for published biomedical articles found that none of the 268 articles 
investigated in the study had provided full access to their data (Iqbal 2016). 
 
This prevalent lack of data sharing across disciplines raises the obvious question 
of why it is the case. A number of factors have been identified in the literature. 
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While funders like the NIH and NSF require that investigators publish and share 
the data from projects they funded, other organizations—such as military 
agencies or private pharmaceutical companies—may, in fact, prohibit 
researchers from making public any data obtained through their funding (Kim & 
Stanton, 2016). In cases where the funding institution neither requires nor 
prohibits the publication of raw data, it is largely up to the researchers to decide 
whether to share it. The fact that data collection can be a difficult and time-
consuming process may make researchers reluctant to share their data before 
making sure they have gotten the most return for their efforts—that is, the most 
possible publication out of that dataset. Another factor that increases the 
likelihood of withholding data is the lack of a standardized method for storing and 
sharing data. This is especially a problem in fields such as engineering and 
ecology, where researchers report spending a significant amount of time 
organizing, uploading, and sharing their data (Kim et al, 2013). With fields such 
as genetics, where data is oftentimes a physical thing such as a reagent or a re-
engineered organism, sharing of data can be an expensive ordeal. Lastly, for 
medical research, in particular, there is the added complexity of the data 
including both clinical and personal information, which—combined with the 
known geographical location of a study—may be sufficient information to unveil 
the identity of the research participants, adding another layer to the problem of 
sharing data (Grover, 2010). 
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When it comes to publishing complete protocols—a document which describes in 
detail every step of a proposed study, standardizes laboratory methods and 
therefore assists in successfully replicating the study—the situation is not much 
better. A 2016 study by Iqbal et al. found that of 268 randomly sampled 
biomedical journal articles, which contained empirical data and were therefore 
expected to include study protocols, only a single article had a full protocol. A 
separate study looking into randomized trials funded by the Canadian Institute of 
Health Research found that in 40% of the investigated papers, major 
discrepancies in primary outcomes existed between the protocol and publication. 
One possible explanation, the researchers suggest, is that formal changes were 
made to the protocol, but were not updated in the version that was made public 
(Chan et al, 2004). The lack of a clear and full protocol for many studies, 
combined with the possibility that even for studies where a protocol is available, it 
may not be a true description of the study, make replication challenging. 
 
Fraud 
Though not as significant a reason for the crisis of reproducibility, scientific 
misconduct is nonetheless a contributing factor. Fang et al., who in 2012 
conducted a review of all biomedical and life-science research articles indexed 
by PubMed as retracted, claimed that 43.4% of the 2,047 identified papers were 
retracted due to suspected or confirmed fraud (Fang, Steen, & Casadevall, 
2012). Fraudulent behavior includes fabrication of results—that is, reporting 
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results that were not obtained—and falsification—which refers to the 
manipulation of different aspects of the research, including its results. 
Engagement in fraudulent behavior by scientists contributes to the problem of 
irreproducibility on multiple levels. First, the results of such studies cannot be 
reproduced, as they were either falsified or fabricated. Second, scientific studies 
which were derived from fraudulent behavior are cited by other studies, leading 
to propagation of faulty and irreproducible data in the scientific literature. 
Moreover, results of papers derived from scientific misconduct continue to be 
cited even after the original article had been retracted (Bornemann-Cimenti, 
Szilagyi, & Sandner-Kiesling, 2016).   
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WHAT CAN BE DONE 
 
 
Perhaps ironically, one way to combat the factors that contribute to the crisis of 
reproducibility is more reproducibility. In theory, more reproduction attempts 
would increase the likelihood of identifying irreproducible results, thereby fulfilling 
its role as a mechanism for self-correction. However, without proper incentives to 
encourage pursuit and publication of negative results, and a reduced emphasis 
on novelty over quality, this is unlikely to happen.  
 
Many of the proposed solutions address individual causes of irreproducibility. For 
example, journals devoted to the publication of negative results (such as Journal 
of Negative Results) had been suggested as a way to address publication biases 
that lead to overwhelmingly positive results in the literature. However, such 
journals are likely to fail for a number of reasons. First, it does not address the 
current incentives driving researchers to publish in prestigious, high-impact 
journals, and since negative-result journals are unlikely to become prestigious or 
high-impact, scientists are unlikely to seek publications in such journals. Second, 
it had been shown that the relative scarcity of negative results in the literature is 
likely a function of failure to submit such studies for publication, and not a 
selection bias by journals. Another proposed strategy, meant to address quality 
control issues, is that the NIH begin requiring cell-line authentication to be 
conducted when submitting grant applications that involve the use of cell-lines 
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(Neimark, 2015) reasonable solution, it may be hindered by the current lack of 
cheap, fast authentication tools, and does not address the larger issues affecting 
reproducibility.  
 
A possible strategy to tackle the bigger picture issues is requiring any publication 
claiming new results to include replication of their findings (Begley & Ellis, 2012). 
Such a requirement could work in cases where data collecting is relatively easy, 
yet it would be nearly impossible for large-scale studies where data collection 
could take years. Furthermore, it has the potential of deterring researchers from 
taking risks or seeking innovation due to the trouble involved with replicating their 
findings (Nosek, Spies, & Motyl, 2012).  
 
An effective solution should address not just specific causes of the problem, but 
the core of it as well. At its core, the problem of irreproducibility—whether it’s due 
to biases, bad statistics, fraud, unavailability of complete data or protocol, data 
interpretation, or poor quality control—stems from the current system which 
favors innovation and extreme results over careful analysis. Increased 
transparency had been suggested as a way to solve this problem. In the short 
term, transparency would help eliminate the individual causes responsible for the 
crisis of reproducibility. More importantly, in the long term, it will help shift the 
focus of science from personal achievements (in the form of groundbreaking 
publications in high-impact journals) to collaborative knowledge accumulation. 
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One way to achieve transparency is through “Open Science.” The idea behind 
open science is that scientists would share their complete methods, data, and 
results in easily and freely accessible databases (Nuzzo, 2015). Making 
complete data and methods public would make data-sharing simpler, and allow 
other researchers to replicate studies and verify the results. It would also allow 
other scientists to identify potential errors in experimental design or data 
interpretation, and could serve as a tool to “outsource” data interpretation in order 
to avoid the issues discussed earlier. Increased transparency would also serve to 
deter scientists from engaging in fraudulent behavior.  
 
To further eliminate biases, researchers would be required to publish a pre-study 
document detailing their proposed research, what data—and how much of it—will 
be collected, what relationships will be investigated, and what statistical methods 
will be utilized (Dickersin, 2015). Such a pre-study document will prevent 
publication and outcome reporting bias, as researchers will be expected to 
publish the results of all conducted investigations, as reported in the pre-study 
document, regardless of the direction or strength of the results. It will also 
prevent sample-size manipulation.  
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CONCLUSION 
 
The crisis of reproducibility in science is widespread across multiple fields. The 
reasons for the crisis are numerous, yet they all stem from the current scientific 
culture of promoting competitiveness over collaboration. In this landscape, 
novelty and positive results are valued more than the pursuit of additional 
evidence for or against already published studies; researchers are rewarded for 
their results, not the quality of their research, and are therefore more likely to 
engage in questionable practices (such as statistical manipulations, foregoing 
quality control, or fraud); there is no incentive to share data among scientists. 
This, in turn, leads to decreased trust in scientific claims and wasting of valuable 
resources.  
 
Attempts to fix the problem of reproducibility, and by extension the problem of 
“bad science,” should focus on increasing transparency. In fact, a shift towards 
more open science is already underway. The Center for Open Science was 
launched in 2013 with a mission to “increase openness, integrity, and 
reproducibility of research” (https://cos.io/). Projects such as Dataverse 
(https://dataverse.org) and Dryad (https://datadryad.org) are offering open 
databases for sharing and analyzing data. Journals are increasingly adopting 
policies to encourage open science (Munafò et al, 2017). On a legislative scale, 
attempts to promote open science include a 2016 document drafted by Dutch 
scientists, The Amsterdam Call for Action on Open Science, which calls for full 
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and open access for all scientific publications, and promotes an environment 
where “data sharing and stewardship is the default approach for all publically 
funded research” (Vollmer, 2016).  
 
This current movement towards an open science is promising and has the 
potential to make science more collaborative, replicable, and transparent. 
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PART II 
 
INTRODUCTION 
 
The second part of the thesis will focus on instances of research misconduct and 
their associated retraction notices. Specifically, it will present data on the fate of 
NIH-funded research publications that have been found to contain data derived 
from scientific misconduct, and investigate the nature of retraction notices 
associated with those publications.  
 
Retractions on the Rise 
Retractions of scientific papers are on the rise; in the decade spanning 2000 to 
2009, there was a tenfold increase in the number of published retractions (Wager 
& Williams, 2011). According to Retraction Watch, there were a total of 684 
retractions in the scientific literature in 2015 as compared to 467 in 2013. 
Notably, in the biomedical sciences, the percent increase in retractions is 
outpacing the increase in the total number of overall publications (McCook, 
2016).   
 
While there are various reasons for retracting a paper, most can be broadly 
categorized as attributable to unintentional errors or due to research misconduct. 
The latter category includes articles in which authors volitionally engaged in 
fabrication or falsification of data, or plagiarism. Just as is the case with 
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retractions in general, retractions due to scientific misconduct are thought to be 
on the rise (Fang et al, 2012).  
 
Though guidelines for retraction notices underscore the importance of full 
transparency (Kleinert, 2009), it remains unknown to what extent authors who 
engage in research misconduct inform readers that research misconduct has 
occurred. Indeed, individual journals may not have clear policies regarding what 
is an appropriate composition of a retraction notice, particularly in cases of 
misconduct. Moreover, there is the basic issue as to whether there is a retraction 
at all in these circumstances.  
 
It is noteworthy that previous work in this area focused on published retraction 
notices, evaluating the percent where research misconduct was cited as a cause 
(Steen, 2011; Fang et al, 2012; Grieneisen & Zhang, 2012; Damineni et al, 
2015). Since we cannot be certain that all papers associated with research 
misconduct are retracted or even whether authors admit to misconduct in 
published retractions, these types of analyses are limited. To understand the 
nature of retractions in this context, therefore, requires following the fate of 
papers documented to involve misconduct. 
 
To begin to address this complex issue, we utilized the Office of Research 
Integrity database. This approach allowed us to identify a population of 
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publications that resulted from research misconduct and, in turn, to assess their 
associated retraction notices. Specifically, we determined the presence or 
absence of a notice, its composition, and whether there were correlations with 
journal impact factor.   
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METHODS 
 
Identification of Articles Involved in Research Misconduct 
The Office of Research Integrity in the US Department of Health and Human 
Services maintains a website (https://ori.hhs.gov/) that lists Case Summaries with 
names of investigators who engaged in documented research misconduct on 
projects supported by NIH funding. The outcomes of investigations into these 
cases along with the titles of associated published articles that contain data 
obtained by research misconduct are detailed. For some investigations, Case 
Summaries were published in a newsletter also available at the website. All such 
listed published articles for a 10-year period (2007-2017) formed the basis of this 
investigation. 
 
These articles were searched on PubMed to determine if there were published 
retractions and to assess the quality of any published retraction through a scoring 
system that was developed. In addition, the impact factor (IF) of the journal was 
recorded. Impact factors were obtained from the Web of Science from the year in 
which the article was retracted, except in one case where the article was 
retracted after the original journal ceased publication. In this case, the most 
recent available IF was used. If there was no retraction, the IF of the year in 
which the ORI published its misconduct findings was used. 
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Assessment and Scoring of Retraction Notices 
We drew upon the retraction guidelines established by the Committee on 
Publication Ethics (COPE) and the International Committee of Medical Journal 
Editors to identify four elements of an optimal retraction notice. These include: (1) 
identity of the author who initiated the retraction; (2) use of unambiguous 
language that communicates the reason for retraction is research misconduct; (3) 
identity of the author responsible for the misconduct; and (4) identification of 
data/figures that are not valid and led to the retraction. Notices received a point 
for of each of these elements. In addition, a single point was given for the mere 
publication of a retraction notice, independent of whether they contained any of 
these elements. Scores thus ranged from 0 to 5 with 0 accorded if there was no 
published retraction and 5 for published retractions that contained all 4 elements 
(table 1). So-called corrections, expressions of concern, or paper withdrawal 
were scored 0. 
 
Statistical Analysis  
All data were analyzed using SAS Studio software, version 3.71 (Cary, NC). We 
calculated total scores for each incident of research misconduct based on our 
retraction scoring system, described by mean and standard deviation. We 
assessed for an association between journal impact factor and mean retraction 
score using ANOVA. In subanalyses, we assessed only incidents of research 
misconduct for which no retraction was issued, using Fisher’s exact test to 
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determine an association between journal impact factor and whether a retraction 
was issued. A two-sided alpha &lt;0.05 was consider the threshold for statistical 
significance 
 
 
Table 1. Retraction Notice Scoring System. Summary of scoring system used 
to evaluate and score retraction notices of paper retracted due to scientific 
misconduct. Retraction notices were awarded either 0 or 1 points based on 5 
criteria, for a total score ranging from 0 to 5.  
 
  Points Awarded 
  1 0 
 Retraction notice present? Yes No 
Author initiated retraction? Yes No 
Does retraction notice state findings of 
misconduct? 
Yes No 
Is responsible author identified? Yes No 
Does notice specify affected data/figures? Yes No 
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RESULTS 
 
Using this database, we identified 200 papers that contained data derived from 
documented misconduct. Of those papers, 42/200 (21%) were not retracted as of 
November 2017. The 42 unretracted papers include 9 instances for which a 
correction was published, 1 expression of concern, and 2 withdrawals with no 
retraction notices. The remaining 30 papers, representing 15% of all identified 
papers, were not retracted and had no associated notices.  
 
The median retraction score of all identified papers was 3 with a mean of 2.62 +/-
1.68. When excluding unretracted papers (score of 0), the median and mean 
scores were 3 and 3.32 +/-1.11, respectively. The score distribution is shown in 
figure 1.   
 
With regard to scoring elements, 67% (109/158) of published retraction notices 
specified which data/figures were derived by misconduct; 63.9% (101/158) cited 
misconduct as the reason for retraction; 52.5% (83/158) were initiated by the 
authors; and 46.8% (73/158) identified the author responsible for the misconduct 
(figure 2). 
 
In the 200 papers identified in this study, there were a total of 65 authors 
identified by the ORI as guilty of research misconduct. Twenty-four of those 
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individuals authored papers which were not retracted. One author was 
responsible for 10 unretracted papers, while the rest of the 32 unretracted papers 
were distributed among 23 different authors.  
 
Publication dates for the unretracted papers range from March 1993 to April 
2016. In total, 3 papers were published prior to 2000, 25 between 2000-2009, 
and 14 on or after 2010. The dates on which the ORI concluded its research 
misconduct investigations that encompassed these 42 papers were distributed as 
follows: 8 prior to 2010, 28 during 2010-2015, and 6 after 2015. Notably, for 2 of 
the unretracted papers the ORI published its findings of research misconduct in 
2017.   
 
Journal impact factors for papers identified in our study range from 0.38 to 53.3. 
The average impact factor was 7.46, with a median of 4.73. No significant 
association was found between impact factor and retraction score. A trend 
toward journals with higher impact factor being more likely to retract a paper was 
observed, though the sample size may be too small to confidently determine. 
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Figure 1. Distribution of Retraction Notice Scores. Total scores for retraction 
notices were distributed as follows: 42 retraction notices received a score of 0; 7 
received score of 1; 31 received score of 2; 53 received score of 3; 39 received 
score of 4; 28 received score of 5.  
 
Figure 2. Frequency of Individual Scoring Elements. Some scoring criteria were 
more likely to be present in retraction notices. For each scoring element, graph 
shows the total number of retraction notices satisfying that criterion.  
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DISCUSSION 
 
Summary of Findings  
In order to examine the status and quality of retraction notices in papers 
associated with research misconduct, we took advantage of information available 
at the ORI website. We found that 21% of such papers have not been retracted 
with an associated retraction notice at the time this study was conducted. 
Importantly, 39/42 of unretracted papers identified were published prior to 2015. 
In this regard, it is estimated that, for articles published after 2002, the average 
time span between publication to retraction is just under 2 years (Casadevall & 
Fang, 2013). Based on this, we believe that the lack of retraction notices is not 
explainable by the timing of publication.  
 
Of the retracted papers that did have an associated retraction notice (158/200), 
the most frequently present scoring element (67%) was information detailing 
which figure(s) or data were incorrect. The least common element (46.8%) was 
information regarding the identification of the author who engaged in research 
misconduct. Notably, only 63.9% of retraction notices stated in unambiguous 
language that the reason for retraction was misconduct. In our study, we did not 
find any statistically significant relationship between overall and individual scoring 
elements and impact factor. 
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Limitations  
Given that 6/42 of unretracted papers identified were from ORI investigations that 
concluded on or after 2015, it is possible that in the future more of those papers 
will be retracted. Another limitation of our study is the relatively small sample 
size.  
 
Implications 
In order to correct the scientific record and restore trust, it is essential that 
retraction notices be transparent and forthcoming, containing all essential 
elements. Though the information presented in retraction notices depends, in 
part, on individual journals’ policies, the Committee on Publication Ethics (COPE) 
provides guidelines for writing such notices. While COPE has over 12,000 
member journals, our findings indicate that for 36% of published retractions, 
there was no mention of research misconduct, demonstrating poor adherence to 
COPE guidelines. A possible solution, which had been previously proposed 
(Moylan & Kowalczuk, 2016), is the adoption of a checklist containing key 
elements identified by COPE that authors have to provide when preparing 
retraction notices. 
 
To ensure that articles identified as containing data derived from research 
misconduct are retracted in a timely manner, we suggest that submission of 
retraction notices be part of the final process that concludes an investigation. If 
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authors refuse, this information should be conveyed and published in the journal. 
One possibility is for journals to provide links to ORI published investigations. 
 
Retracting papers due to scientific misconduct and publication of an appropriate 
Collaboration between authors, funding agencies, research institutions, and 
journals, as well as the establishment of clear adherent guidelines for dealing 
with the process of retraction and publication of retraction notice are essential. 
This would help speed the process of retraction, improve transparency, enhance 
a culture of integrity and rigor, and improve scientific credibility amongst the lay 
public.  
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